Stock Market News for December 24, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Dec 24, 9:10AM CST
Benchmarks mostly settled in the green on Tuesday banking on better-than-expected revision to third quarter GDP numbers
KMI: 42.01 (+0.10), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), MON: 120.97 (-1.70), AMGN: 160.67 (+3.15), XOM: 93.78 (-0.81), BA: 131.24 (+1.21), SLB: 87.06 (-0.26), CELG: 109.60 (+3.48), LYB: 81.31 (-0.89), REG: 64.30 (-0.04), DD: 74.79 (-0.40), CVX: 113.47 (-0.48), OXY: 82.24 (-0.66), PX: 131.74 (-0.35), DOW: 46.01 (+0.03)
Biotech Stock Roundup: AbbVie's HCV Treatment Approved, ImmunoGen Plunges on Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 24, 8:48AM CST
Will Express Scripts' announcement regarding AbbVie's (ABBV) Viekira Pak lead to a pricing war in the hepatitis C virus (HCV) market?
BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), IMGN: 5.90 (+0.13), ABBV: 66.21 (+1.86)
After Yesterday's Decline of 2.51%, Vertex Pharmaceuticals Offers Investors Better Value
Comtex SmarTrend(R) - Tue Dec 23, 3:55PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $109.34 to a high of $119.54. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $111.66 on volume of 4.1 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
VRTX: 115.15 (+1.40)
Insider Buys And Sells: American Homes 4 Rent, Western Gas Partners
Asif Suria - at Seeking Alpha - Mon Dec 22, 3:50PM CST
Welcome to edition 235 of Insider Weekends. The prolific buying by insiders of energy companies lost some steam last week even as oil and energy stocks rebounded sharply along with the rest of the market. With the S&P 500 closing less than 5...
RH: 96.97 (-0.16), AMH: 17.34 (-0.07), VRTX: 115.15 (+1.40), CODI: 15.99 (-0.11), RES: 13.26 (-0.35), LJPC: 16.35 (-0.10), ICE: 221.73 (-1.70), WES: 73.08 (-0.25), ENH: 59.60 (-0.55), GHC: 877.19 (-0.76)
Vertex Pharmaceuticals Up 25.4% Since SmarTrend Uptrend Call (VRTX)
Comtex SmarTrend(R) - Mon Dec 22, 9:45AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 25.44% as of today's recent price of $120.25.
VRTX: 115.15 (+1.40)
After Hour Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Dec 19, 4:36PM CST
NG: 2.82 (+0.10), VRTX: 115.15 (+1.40), NBR: 12.42 (-0.26), SAND: 3.19 (+0.32), MRKT: 26.55 (-0.14), NEM: 18.57 (+0.53), EDU: 20.35 (-0.04), DNR: 8.15 (-0.18), MCHX: 5.20 (-0.05), CRK: 7.01 (-0.20)
Adam Feuerstein's 2014 Biotech Stock Report Card (No Grading on a Curve)
at The Street - Fri Dec 19, 8:02AM CST
Good calls: Vertex, InterMune, Chelsea, Galena, Exact Sciences. The bad calls: Avanir, Amarin, Exelixis and the bursting biotech stock bubble.
VRTX: 115.15 (+1.40), GALE: 1.49 (-0.02), EXAS: 27.60 (+0.39), ARIA: 6.81 (+0.15), MNKD: 5.68 (+0.18)
2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 88.76 (+3.23), VRTX: 115.15 (+1.40), GILD: 91.29 (+1.84), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), SGMO: 14.20 (+0.14)
InsiderInsights.com Daily Round Up 12/16/14: XOMA, NS, TEP, RES
InsiderInsights - at Seeking Alpha - Wed Dec 17, 2:27PM CST
RH: 96.97 (-0.16), VRTX: 115.15 (+1.40), RES: 13.26 (-0.35), CCO: 10.19 (+0.34), HDS: 29.72 (+0.01), NS: 57.17 (+0.24), MFRM: 59.59 (+0.68), PCLN: 1,149.78 (+2.17), HERO: 1.05 (-0.02), TEP: 42.75 (+0.68), LC: 25.32 (+2.24), WIW: 11.28 (+0.03), FII: 33.86 (+0.26), HMTV: 12.81 (-0.03), DYN: 29.42 (+0.12), TWTR: 37.61 (+0.04), FOXF: 16.15 (+0.07), YUM: 72.79 (+0.11), WIA: 11.55 (+0.06), XOMA: 3.68 (+0.11)
2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), NBIX: 21.33 (+0.09), GILD: 91.29 (+1.84), ARWR: 6.35 (+0.07), SRPT: 13.88 (+0.47), MRK: 57.46 (+0.25), CTIC: 2.36 (+0.05), CEMP: 20.66 (+0.78), BMY: 59.15 (-0.01)
Where Are They Now? A Look Back at the Best & Worst Biotech CEOs
at The Street - Tue Dec 16, 10:20AM CST
One biotech CEO won accolades in 2010 only to be razzed for poor performance in 2011.
VRTX: 115.15 (+1.40), MYGN: 36.50 (+0.28), DNDN: 0.13 (-0.02), CTIC: 2.36 (+0.05), REGN: 400.12 (+6.07), CELG: 109.60 (+3.48)
Shares of VRTX Up 22.4% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Mon Dec 15, 9:18AM CST
SmarTrend identified an Uptrend for Vertex Pharmaceuticals (NASDAQ:VRTX) on September 18th, 2014 at $95.87. In approximately 3 months, Vertex Pharmaceuticals has returned 22.41% as of today's recent price of $117.35.
VRTX: 115.15 (+1.40)
David Altshuler, M.D., Ph.D., Joins Vertex as Executive Vice President of Global Research and Chief Scientific Officer
Business Wire - Mon Dec 15, 8:01AM CST
Vertex Pharmaceuticals Incorporated today announced that David Altshuler, M.D., Ph.D., will join the company as Executive Vice President, Global Research and Chief Scientific Officer. Dr. Altshuler was one of the four founding members of the Broad Institute of Harvard University and the Massachusetts Institute of Technology, where he has served as Deputy Director and Chief Academic Officer since 2009. Dr. Altshuler is also currently a Professor of Genetics and Medicine at Harvard Medical School and an Adjunct Professor of Biology at the Massachusetts Institute of Technology and has been an attending physician at the Massachusetts General Hospital. His scientific research has been focused on the discovery of new pathophysiological processes underlying the risk of developing type 2 diabetes to identify and validate new drug targets. At Vertex, Dr. Altshuler will lead the company's research efforts aimed at discovering new medicines for the treatment of serious diseases, overseeing activities across the company's five research sites in the United States, Canada and Europe.
VRTX: 115.15 (+1.40)
Top Healthcare Stocks for 2014
Todd Campbell, The Motley Fool - Motley Fool - Sun Dec 14, 10:03AM CST
Source: Flickr user Tax Credits . This past year has been a great one for healthcare investors -- the S&P healthcare index ETF offered double the return of the S&P 500. Biotechnology stocks dominated the list of the 10 top-performing...
MNK: 97.84 (-0.29), MDVN: 99.23 (+1.23), CNC: 105.96 (+1.03), AGN: 210.12 (+0.95), VRTX: 115.15 (+1.40), ALNY: 93.52 (+0.97), EW: 130.75 (+1.17), ILMN: 186.22 (+2.72), SNY: 46.35 (+0.50), REGN: 400.12 (+6.07), PBYI: 189.96 (+0.12)
Watch for Vertex Pharmaceuticals to Potentially Pullback After Gaining 3.05% Yesterday
Comtex SmarTrend(R) - Thu Dec 11, 4:02PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.15 (+1.40)
After Yesterday's Rally of 3.05% Shares Could Potentially Pullback
Comtex SmarTrend(R) - Thu Dec 11, 4:01PM CST
Vertex Pharmaceuticals (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $117.85 to a high of $122.26. Yesterday, the shares gained 3.1%, which took the trading range above the 3-day high of $121.65 on volume of 1.3 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
VRTX: 115.15 (+1.40)
Why Gilead Sciences and AbbVie Care About This Tiny Company
Todd Campbell, The Motley Fool - Motley Fool - Thu Dec 11, 9:18AM CST
Source: Gilead Sciences via Google Maps. Investors are focusing on AbbVie 's hepatitis C drug and its potential impact on Gilead Sciences ' hepatitis C market share if it wins FDA approval later this month. However, they might also want to keep...
VRTX: 115.15 (+1.40), GILD: 91.29 (+1.84), ACHN: 13.06 (+1.22), ABBV: 66.21 (+1.86)
Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Dec 10, 2:10PM CST
Yet another acquisition agreement was announced even as the biotech sector was busy with showcasing data at ASH.
BLUE: 88.76 (+3.23), BIIB: 340.89 (+5.13), VRTX: 115.15 (+1.40), CBST: 100.29 (-0.09), INCY: 71.57 (+1.99), AMGN: 160.67 (+3.15), ARRY: 4.64 (+0.07)